- Hutchison China MediTech said the study on its cancer treatment would be stopped after the independent Data Monitoring Committee determined that the study had already met its primary objective of improving survival rates in patients suffering from pancreatic cancer.

'SANET-ep is a Phase III study in China of surufatinib in patients with low- or intermediate-grade advanced extra-pancreatic neuroendocrine tumors patients for whom there is no effective therapy,' the company added/

The primary endpoint of the study was to evaluate whether the company's cancer treatment surufatinib improved survival rates in patients suffering from pancreatic cancer.

Chi-Med said it would now arrange for a pre-New Drug Application meeting with the China National Medical Products Administration to discuss the preparation of the NDA for surufatinib. 'We intend to submit the results of the SANET-ep study for presentation at an upcoming scientific conference,' the company said.

At 10:01am: [LON:HCM] Hutchison China Meditech Ltd share price was +19.25p at 437.5p

Story provided by